Biomarkers in Prediction of AMI

NCT ID: NCT06212921

Last Updated: 2024-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-14

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Current study will be undertaken to identify combinations of biomarkers that can reliably identify acute mesenteric ischaemia (AMI) and distinguish between non-transmural and transmural ischaemia. Different combinations of biomarkers for different sub-types and severity of AMI, and different time points of measurement after onset of symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Mesenteric Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Sequential blood samples will be collected from study subjects
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with suspicion of acute mesenteric ischaemia

Bolld samples is the only intervention. All patients with suspicion of AMI will be included and blood samples collected

Group Type OTHER

Sequential blood samples

Intervention Type DIAGNOSTIC_TEST

Sequential blood samples for diagnostic tests is the only intervention in thei study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sequential blood samples

Sequential blood samples for diagnostic tests is the only intervention in thei study

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older
* Initial decision in favour of further diagnostics of mesenteric ischaemia

Exclusion Criteria

* Age \<18 years
* Consent declined by patient or next of kin (delayed consent)
* Chronic mesenteric ischaemia without an acute event
* Immediate decision for withdrawal of further diagnostics and active treatment
* Referral from another hospital with already established diagnosis of AMI
* AMI diagnosed at surgery without previously having been considered
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Tartu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Annika Reintam Blaser

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tartu University Hospital

Tartu, , Estonia

Site Status RECRUITING

Lucerne Cantonal Hospital

Lucerne, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Estonia Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Annika Reintam Blaser, PhD

Role: CONTACT

+3725142281

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Joel Starkopf, PhD

Role: primary

+3727318405

Juan Celi de la Torre, MD

Role: primary

+41412051886

References

Explore related publications, articles, or registry entries linked to this study.

Tamme K, Acosta S, Biloslavo A, Bjorck M, Casian D, Damaskos D, Forbes A, Kase K, Kisand K, Lakbar I, Mihnovits V, Murruste M, Mandul M, Nuzzo A, Padar M, Starkopf J, Visconti D, Reintam Blaser A. Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol. BMC Surg. 2024 Jul 3;24(1):201. doi: 10.1186/s12893-024-02491-3.

Reference Type DERIVED
PMID: 38961419 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BIPAMI study

Identifier Type: -

Identifier Source: org_study_id